{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:14:07Z","timestamp":1784189647841,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["310030_219969"],"award-info":[{"award-number":["310030_219969"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CSL Behring AG, Switzerland","award":["Research Acceleration Initiative"],"award-info":[{"award-number":["Research Acceleration Initiative"]}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","award":["Intramural Funds"],"award-info":[{"award-number":["Intramural Funds"]}],"id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52102-9","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T18:23:25Z","timestamp":1778955805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways"],"prefix":"10.1038","volume":"16","author":[{"given":"Aleksandra","family":"Blagojevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"R\u00fcthemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Caglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Tiric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew Ebin","family":"Sovichan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Pouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Huber-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ricklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"52102_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785\u2013797 (2010).","journal-title":"Nat. Immunol."},{"key":"52102_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","volume":"24","author":"DC Mastellos","year":"2024","unstructured":"Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. A guide to complement biology, pathology and therapeutic opportunity. Nat. Rev. Immunol. 24, 118\u2013141 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"52102_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system Part I - molecular mechanisms of activation and regulation. Front. Immunol. 6, 262 (2015).","journal-title":"Front. Immunol."},{"key":"52102_CR4","doi-asserted-by":"crossref","unstructured":"Hevey, R., Pouw, R. B., Harris, C. & Ricklin, D. Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. Br. J. Pharmacol. 178, 2802\u20132822 (2021).","DOI":"10.1111\/bph.15307"},{"key":"52102_CR5","doi-asserted-by":"publisher","unstructured":"Pouw, R. B. & Ricklin, D. Tipping the balance: Intricate roles of the complement system in disease and therapy. Semin. Immunopathol. 43, 757\u2013771 (2021). https:\/\/doi.org\/10.1007\/s00281-021-00892-7","DOI":"10.1007\/s00281-021-00892-7"},{"key":"52102_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","volume":"12","author":"D Ricklin","year":"2016","unstructured":"Ricklin, D., Reis, E. S. & Lambris, J. D. Complement in disease: A defence system turning offensive. Nat. Rev. Nephrol. 12, 383\u2013401. https:\/\/doi.org\/10.1038\/nrneph.2016.70 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"52102_CR7","doi-asserted-by":"publisher","first-page":"e2350816","DOI":"10.1002\/eji.202350816","volume":"54","author":"D Ricklin","year":"2024","unstructured":"Ricklin, D. Complement-targeted therapeutics: Are we there yet, or just getting started? Eur. J. Immunol.\u00a054, e2350816 (2024).","journal-title":"Eur. J. Immunol."},{"key":"52102_CR8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","volume":"147","author":"A Greco","year":"2023","unstructured":"Greco, A. et al. Pharmacology and clinical development of factor XI inhibitors. Circulation 147, 897\u2013913 (2023).","journal-title":"Circulation"},{"key":"52102_CR9","doi-asserted-by":"publisher","first-page":"B65","DOI":"10.1093\/eurheartjsupp\/suad070","volume":"25","author":"F Muscente","year":"2023","unstructured":"Muscente, F. & De Caterina, R. The new in anticoagulation: Factor XI inhibitors. Eur. Heart J. Supplement. 25, B65\u2013B68 (2023).","journal-title":"Eur. Heart J. Supplement"},{"key":"52102_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jth.13194","volume":"14","author":"AH Schmaier","year":"2016","unstructured":"Schmaier, A. H. The contact activation and kallikrein\/kinin systems: Pathophysiologic and physiologic activities. J. Thromb. Haemost. 14, 28\u201339 (2016).","journal-title":"J. Thromb. Haemost."},{"key":"52102_CR11","doi-asserted-by":"publisher","first-page":"1000172","DOI":"10.3389\/fimmu.2022.1000172","volume":"13","author":"IF Delaura","year":"2022","unstructured":"Delaura, I. F. et al. Complement-targeting therapeutics for ischemia-reperfusion injury in transplantation and the potential for ex vivo delivery. Front. Immunol. 13, 1000172 (2022).","journal-title":"Front. Immunol."},{"key":"52102_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1055\/s-0031-1276585","volume":"37","author":"S Zeerleder","year":"2011","unstructured":"Zeerleder, S. C1-inhibitor: more than a serine protease inhibitor. Semin Thromb. Hemost. 37, 362\u2013374 (2011).","journal-title":"Semin Thromb. Hemost."},{"key":"52102_CR13","doi-asserted-by":"publisher","first-page":"103890","DOI":"10.1016\/j.drudis.2024.103890","volume":"29","author":"L Ding","year":"2024","unstructured":"Ding, L., Zhang, M. J. & Rao, G. W. Summary and future of medicine for hereditary angioedema. Drug Discov Today. 29, 103890 (2024).","journal-title":"Drug Discov Today"},{"issue":"1","key":"52102_CR14","doi-asserted-by":"publisher","first-page":"602277","DOI":"10.3389\/fimmu.2021.602277","volume":"12","author":"SR Moore","year":"2021","unstructured":"Moore, S. R., Menon, S. S., Cortes, C. & Ferreira, V. P. Hijacking Factor H for complement immune evasion. Front. Immunol. 12,\u00a0602277\u00a0(2021).","journal-title":"Front. Immunol."},{"key":"52102_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1515\/hsz-2012-0174","volume":"393","author":"M Potempa","year":"2012","unstructured":"Potempa, M. & Potempa, J. Protease-dependent mechanisms of complement evasion by bacterial pathogens. Biol. Chem. 393, 873\u2013888 (2012).","journal-title":"Biol. Chem."},{"key":"52102_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3389\/fphar.2020.01132","volume":"11","author":"K de Bordon","year":"2020","unstructured":"de Bordon, K. From animal poisons and venoms to medicines: Achievements, challenges and perspectives in drug discovery. Front. Pharmacol. 11, 1132 (2020).","journal-title":"Front. Pharmacol."},{"key":"52102_CR17","unstructured":"Seale, L. & Finney, S. Polypeptides, dna coding therefor, formulations thereof, and their use in inhibiting factor xii activation. Patent No. WO1999036439A1 (1998)."},{"key":"52102_CR18","unstructured":"West, R. R., Sheppard, P. O. & Fox, B. A. Peptide and polypeptide inhibitors of complement C1s. Patent No. US20020102256A1 (2005)."},{"key":"52102_CR19","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.4049\/jimmunol.1700158","volume":"199","author":"SS Pang","year":"2017","unstructured":"Pang, S. S. et al. The Structural Basis for Complement Inhibition by Gigastasin, a Protease Inhibitor from the Giant Amazon Leech. J. Immunol. 199, 3883\u20133891 (2017).","journal-title":"J. Immunol."},{"key":"52102_CR20","doi-asserted-by":"publisher","unstructured":"Scott, D. E., Spry, C. & Abell, C. Differential scanning fluorimetry as part of a biophysical screening cascade. In Fragment-based Drug Discovery Lessons and Outlook (Erlanson, D. A. & Jahnke, W. eds.) 139\u2013172 (2016). https:\/\/doi.org\/10.1002\/9783527683604.ch07","DOI":"10.1002\/9783527683604.ch07"},{"key":"52102_CR21","doi-asserted-by":"crossref","unstructured":"Tombling, B. J., Onan, C., Wang, K. & Craik, D. J. EGF-likeand other disulfide-rich microdomains as therapeutic scaffolds. Angew. Chem. Int. Ed. Engl.  59, 1218\u201311232 (2020).","DOI":"10.1002\/anie.201913809"},{"key":"52102_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/febs.14696","volume":"286","author":"AO Magnusson","year":"2019","unstructured":"Magnusson, A. O. et al. nanoDSF as screening tool for enzyme libraries and biotechnology development. FEBS J. 286, 184\u2013204 (2019).","journal-title":"FEBS J."},{"key":"52102_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/jps.22267","volume":"100","author":"LA Brito","year":"2011","unstructured":"Brito, L. A. & Singh, M. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J. Pharm. Sci. 100, 34\u201337 (2011).","journal-title":"J. Pharm. Sci."},{"key":"52102_CR24","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1016\/j.biomaterials.2005.04.063","volume":"26","author":"MB Gorbet","year":"2005","unstructured":"Gorbet, M. B., Sefton, M. V. & Endotoxin The uninvited guest. Biomaterials 26, 6811\u20136817 (2005).","journal-title":"Biomaterials"},{"key":"52102_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/jth.14882","volume":"18","author":"A Amgalan","year":"2020","unstructured":"Amgalan, A., Allen, T., Othman, M. & Ahmadzia, H. K. Systematic review of viscoelastic testing (TEG\/ROTEM) in obstetrics and recommendations from the women\u2019s SSC of the ISTH. J. Thromb. Haemost. 18, 1813\u20131838 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"52102_CR26","doi-asserted-by":"publisher","unstructured":"Fishelson, Z. Complement protease c1s. xPharm: Compr. Pharmacol. Ref. 1\u20137 https:\/\/doi.org\/10.1016\/B978-008055232-3.63065-X (2007).","DOI":"10.1016\/B978-008055232-3.63065-X"},{"key":"52102_CR27","doi-asserted-by":"publisher","first-page":"15821","DOI":"10.1074\/jbc.M113.464545","volume":"288","author":"AJ Perry","year":"2013","unstructured":"Perry, A. J. et al. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4. J. Biol. Chem. 288, 15821\u201315829 (2013).","journal-title":"J. Biol. Chem."},{"key":"52102_CR28","doi-asserted-by":"publisher","first-page":"29987","DOI":"10.1074\/jbc.272.48.29987","volume":"272","author":"JJ Perona","year":"1997","unstructured":"Perona, J. J. & Craik, C. S. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J. Biol. Chem. 272, 29987\u201329990 (1997).","journal-title":"J. Biol. Chem."},{"key":"52102_CR29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.imbio.2012.07.024","volume":"217","author":"WB Gorsuch","year":"2012","unstructured":"Gorsuch, W. B., Chrysanthou, E., Schwaeble, W. J. & Stahl, G. L. The complement system in ischemia-reperfusion injuries. Immunobiology 217, 1026\u20131033 (2012).","journal-title":"Immunobiology"},{"key":"52102_CR30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3389\/fimmu.2018.01151","volume":"9","author":"A Panagiotou","year":"2018","unstructured":"Panagiotou, A., Trendelenburg, M. & Osthoff, M. The lectin pathway of complement in myocardial ischemia\/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor. Front. Immunol. 9, 1151 (2018).","journal-title":"Front. Immunol."},{"key":"52102_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOT.0000000000000037","volume":"19","author":"CA Farrar","year":"2014","unstructured":"Farrar, C. A. & Sacks, S. H. Mechanisms of rejection: Role of complement. Curr. Opin. Organ. Transpl. 19, 8\u201313 (2014).","journal-title":"Curr. Opin. Organ. Transpl."},{"key":"52102_CR32","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1111\/j.1600-6143.2011.03646.x","volume":"11","author":"S Chen","year":"2011","unstructured":"Chen, S. et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 11, 2057\u20132066 (2011).","journal-title":"Am. J. Transplant."},{"key":"52102_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrmicro1824","volume":"6","author":"JD Lambris","year":"2008","unstructured":"Lambris, J. D., Ricklin, D. & Geisbrecht, B. V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6, 132\u2013142 (2008).","journal-title":"Nat. Rev. Microbiol."},{"key":"52102_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0049-3848(94)90032-9","volume":"74","author":"F Markwardt","year":"1994","unstructured":"Markwardt, F. The development of hirudin as an antithrombotic drug. Thromb. Res. 74, 1\u201323 (1994).","journal-title":"Thromb. Res."},{"key":"52102_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bjh.16305","volume":"188","author":"S Schols","year":"2020","unstructured":"Schols, S. et al. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan). Br. J. Haematol. 188, 334\u2013337 (2020).","journal-title":"Br. J. Haematol."},{"key":"52102_CR36","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/bjh.13990","volume":"173","author":"F May","year":"2016","unstructured":"May, F. et al. FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis. Br. J. Haematol. 173, 769\u2013778 (2016).","journal-title":"Br. J. Haematol."},{"key":"52102_CR37","doi-asserted-by":"crossref","unstructured":"Simmons, K. T. et al. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s. Clin. Immunol. 251, (2023).","DOI":"10.1016\/j.clim.2023.109629"},{"key":"52102_CR38","unstructured":"Rohlik, D. Development of small-molecule inhibitors of the initiating proteases, C1r and C1s, of the classical complement pathway. (Doctoral thesis, East Carolina University, 2019)."},{"key":"52102_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00001721-199102000-00023","volume":"2","author":"RT Sawyer","year":"1991","unstructured":"Sawyer, R. T., Jones, C. P. & Munro, R. The biological function of hementin in the proboscis of the leech Haementeria ghilianii. Blood Coagul Fibrinolysis. 2, 153\u2013159 (1991).","journal-title":"Blood Coagul Fibrinolysis"},{"key":"52102_CR40","doi-asserted-by":"publisher","first-page":"112878","DOI":"10.1016\/j.biopha.2022.112878","volume":"149","author":"MR Montinari","year":"2022","unstructured":"Montinari, M. R. & Minelli, S. From ancient leech to direct thrombin inhibitors and beyond: New from old. Biomed. Pharmacother. 149, 112878 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"52102_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0003-9861(91)90325-D","volume":"285","author":"EM Nutt","year":"1991","unstructured":"Nutt, E. M. et al. Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa. Arch. Biochem. Biophys. 285, 37\u201344 (1991).","journal-title":"Arch. Biochem. Biophys."},{"key":"52102_CR42","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1021\/jm901743x","volume":"53","author":"M\u00c1 Corral-Rodr\u00edguez","year":"2010","unstructured":"Corral-Rodr\u00edguez, M. \u00c1., MacEdo-Ribeiro, S., Barbosa Pereira, P. J. & Fuentes-Prior, P. Leech-derived thrombin inhibitors: From structures to mechanisms to clinical applications. J. Med. Chem. 53, 3847\u20133861 (2010).","journal-title":"J. Med. Chem."},{"key":"52102_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0014-5793(01)02212-8","volume":"492","author":"M Salzet","year":"2001","unstructured":"Salzet, M. Anticoagulants and inhibitors of platelet aggregation derived from leeches. FEBS Lett. 492, 187\u2013192 (2001).","journal-title":"FEBS Lett."},{"key":"52102_CR44","doi-asserted-by":"publisher","first-page":"e202300744","DOI":"10.1002\/cbic.202300744","volume":"25","author":"TY Chen","year":"2024","unstructured":"Chen, T. Y. et al. Effect of sulfotyrosine and negatively charged amino acid of leech-derived peptides on binding and inhibitory activity against thrombin. Chembiochem 25, e202300744 (2024).","journal-title":"Chembiochem"},{"key":"52102_CR45","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/j.1538-7836.2007.02435.x","volume":"5","author":"DM Monroe","year":"2007","unstructured":"Monroe, D. M. & Key, N. S. The tissue factor\u2013factor VIIa complex: procoagulant activity, regulation, and multitasking. J. Thromb. Haemost. 5, 1097\u20131105 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"52102_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.thromres.2016.04.024","volume":"143","author":"A Landsem","year":"2016","unstructured":"Landsem, A., Fure, H., Mollnes, T. E., Nielsen, E. W. & Brekke, O. L. C1-inhibitor efficiently delays clot development in normal human whole blood and inhibits Escherichia coli-induced coagulation measured by thromboelastometry. Thromb. Res. 143, 63\u201370 (2016).","journal-title":"Thromb. Res."},{"key":"52102_CR47","doi-asserted-by":"crossref","unstructured":"Ali, A. E. et al. Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: A meta-analysis of randomized controlled trials. J. Thromb. Thrombolysis 58, 1\u201314 (2024).","DOI":"10.1007\/s11239-024-02986-z"},{"key":"52102_CR48","doi-asserted-by":"crossref","unstructured":"Galli, M. et al. Therapeutic Potential of FXI Inhibitors: Hype or Hope? Drugs 84, 1055\u20131070 (2024).","DOI":"10.1007\/s40265-024-02049-w"},{"key":"52102_CR49","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1111\/jth.14209","volume":"16","author":"S De Maat","year":"2018","unstructured":"De Maat, S., Hofman, Z. L. M. & Maas, C. Hereditary angioedema: the plasma contact system out of control. J. Thromb. Haemost. 16, 1674\u20131685 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"52102_CR50","doi-asserted-by":"publisher","first-page":"718","DOI":"10.4049\/jimmunol.2400194","volume":"213","author":"RJ Garrigues","year":"2024","unstructured":"Garrigues, R. J., Garrison, M. P. & Garcia, B. L. The crystal structure of the michaelis-menten complex of C1 esterase inhibitor and C1s reveals novel insights into complement regulation. J. Immunol. 213, 718\u2013729 (2024).","journal-title":"J. Immunol."},{"key":"52102_CR51","doi-asserted-by":"publisher","first-page":"852119","DOI":"10.3389\/fimmu.2022.852119","volume":"13","author":"EW Nielsen","year":"2022","unstructured":"Nielsen, E. W. et al. A novel porcine model of ischemia-reperfusion injury after cross-clamping the thoracic aorta revealed substantial cardiopulmonary, thromboinflammatory and biochemical changes without effect of C1-Inhibitor treatment. Front. Immunol. 13, 852119 (2022).","journal-title":"Front. Immunol."},{"key":"52102_CR52","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1128\/CVI.00106-09","volume":"16","author":"R Segura-Vel\u00e1zquez","year":"2009","unstructured":"Segura-Vel\u00e1zquez, R., Fragoso, G., Sciutto, E. & Sarukhan, A. Towards identification of the mechanisms of action of parasite-derived peptide gk1 on the immunogenicity of an influenza vaccine. Clin. Vaccine Immunol. 16, 1338 (2009).","journal-title":"Clin. Vaccine Immunol."},{"key":"52102_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jconrel.2015.08.045","volume":"217","author":"WL Fotoran","year":"2015","unstructured":"Fotoran, W. L. et al. Liposomes loaded with P. falciparum merozoite-derived proteins are highly immunogenic and produce invasion-inhibiting and anti-toxin antibodies. J. Control Rel.. 217, 121\u2013127 (2015).","journal-title":"J. Control Release"},{"key":"52102_CR54","doi-asserted-by":"crossref","unstructured":"Sawyer, R. T., Lepont, F., Stuart, D. K. & Kramer, A. P. Growth and reproduction of the giant glossiphoniid leech haementeria ghilianii. Biol. Bulletin 160, 322\u2013331. https:\/\/www.jstor.org\/stable\/1540892 (1981).","DOI":"10.2307\/1540892"},{"key":"52102_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2016.06.004","volume":"76","author":"J Kotimaa","year":"2016","unstructured":"Kotimaa, J. et al. Sex matters: Systemic complement activity of female C57BL\/6J and BALB\/cJ mice is limited by serum terminal pathway components. Mol. Immunol. 76, 13\u201321 (2016).","journal-title":"Mol. Immunol."},{"key":"52102_CR56","doi-asserted-by":"publisher","unstructured":"Matthiesen, R. & Bunkenborg, J. Introduction to mass spectrometry-based proteomics. Methods Mol. Biol. 1007, 1\u201345. https:\/\/doi.org\/10.1007\/978-1-62703-392-3_1 (2013).","DOI":"10.1007\/978-1-62703-392-3_1"},{"key":"52102_CR57","doi-asserted-by":"crossref","unstructured":"Ferreira, V. P. et al. SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis. Sci. Rep. 6, 19300 (2016).","DOI":"10.1038\/srep19300"},{"key":"52102_CR58","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.4049\/jimmunol.1201085","volume":"189","author":"RC Duncan","year":"2012","unstructured":"Duncan, R. C. et al. Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s. J. Immunol. 189, 2365\u20132373 (2012).","journal-title":"J. Immunol."},{"key":"52102_CR59","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/eji.201445070","volume":"45","author":"MP Keizer","year":"2015","unstructured":"Keizer, M. P. et al. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2. Eur. J. Immunol. 45, 544\u2013550 (2015).","journal-title":"Eur. J. Immunol."},{"key":"52102_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-62703-724-2_2","volume":"1100","author":"A Roos","year":"2014","unstructured":"Roos, A. & Wieslander, J. Evaluation of complement function by ELISA. Methods Mol. Biol. 1100, 11\u201323 (2014).","journal-title":"Methods Mol. Biol."},{"key":"52102_CR61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/pro.3280","volume":"27","author":"E Jurrus","year":"2018","unstructured":"Jurrus, E. et al. Improvements to the APBS biomolecular solvation software suite. Protein Sci. 27, 112\u2013128 (2018).","journal-title":"Protein Sci."},{"key":"52102_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1005659","volume":"13","author":"P Eastman","year":"2017","unstructured":"Eastman, P. et al. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput. Biol. 13, 1\u201317 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"52102_CR63","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713 (2015).","journal-title":"J. Chem. Theory Comput."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52102-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52102-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52102-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:02:49Z","timestamp":1784188969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52102-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52102"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52102-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DR is inventor of patents and patent applications describing complement inhibitors and their therapeutic use, some of which have been licensed to Amyndas. RBP is co-inventor of patents and patent applications describing therapeutic complement-targeting antibodies and uses thereof. DR provided paid services (advisory board, solicited presentations) for companies including Novartis, Roche, Alexion, Sobi, Greenovation and venture capitalists, and received a Research Acceleration Grant from CSL Behring. The other authors declare that they have no conflicts of interest with the contents of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22320"}}